Because Passions Should Rule One’s Life. Not Diabetes!

Diabeloop partners with patients: Since its creation, Diabeloop has been involving people living with Type 1 or Type 2 diabetes and their relatives from the very first phases of development of its innovations, alongside engineers and doctors.

The creation of intuitive interfaces for the personalized solutions developed by Diabeloop are inspired by the requests of patients and their personal experiences, so that they can spend less time on their diabetes, and more on their passions!

The International Launch Of An Young Independent Company

Diabeloop’s first medical device is marketed in France and in several European countries.

We have signed development agreements with several international partners (Roche Diabetes Care, ViCentra, SOOIL, Terumo Corporation, BIOCORP).

To support this international ambition and our Research and Development roadmap, we have finalized our third round of financing in 2022, for a total of 70 million euros.

Reduce The Heavy Burden For People With Diabetes

Diabeloop developed a self-learning algorithm that embeds therapeutic artificial intelligence, to automate Type 1 diabetes treatment. It is intended to relieve people affected by this chronic condition from having to make constant therapeutic decisions every day and night, and to allow them to live life without interruption.

Extended partnership between Diabeloop and Terumo Corporation to develop and commercialize AID solutions in Europe

https://www.mpo-mag.com/contents/view_breaking-news/2022-02-15/terumo-and-diabeloop-partner-to-expand-diabetes-care-offerings/

Diabeloop rounds up 70 million euros to accelerate its international expansion

https://www.fiercebiotech.com/medtech/diabeloop-rounds-eu70m-take-ai-powered-insulin-delivery-tech-global

Conclusion of new global development and commercial agreements with SOOIL Development Company

https://www.massdevice.com/diabeloop-sooil-automated-insulin-diabetes/

Diabeloop completes a 70 million euros Series C to support its hyper growth

https://www.g-medtech.com/news/diabeloop-closes-e70m-series-c-financing-led-by-lbo-france/

Connected insulin pens: Diabeloop announces a new collaboration with Novo Nordisk

https://www.contractpharma.com/contents/view_breaking-news/2023-03-21/diabeloop-novo-nordisk-partner-on-next-gen-insulin-pens/

Awards

French Tech 120 2020

Start Up of the Year 2019 award

InnovEIT Award 2019

Awarding fundings in 2016-2017 and 2018-2019-2020

Trophée de l'Embarqué, Health Award

Born Global Award Start-up of the Year EY 2018

Jury Prize, Start-up of the Year SNITEM

Samsung Artificial Intelligence Award Vivatech 2018